Exact Mass: 597.3386988
Exact Mass Matches: 597.3386988
Found 266 metabolites which its exact mass value is equals to given mass value 597.3386988
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
1-Oleoyl-sn-glycero-3-phospho-D-myo-inositol(1-)
Revefenacin
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03B - Other drugs for obstructive airway diseases, inhalants > R03BB - Anticholinergics C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Revefenacin (TD-4208; GSK1160724) is a potent mAChR antagonist; has a high affinity on M3 receptor with a Ki of 0.18 nM.
(1alpha,6alpha,14alpha)-8-acetoxy-1,6,16-trimethoxy-4-(methoxymethyl)aconitan-14-yl 4-methoxybenzoate|macrorhynine A
6alpha-hydroxynorcassamide 22-O-beta-D-galactopyranoside
5alpha-acetyloxy-15beta-hydroxy-3beta-isovaleryloxy-2alpha-nicotinyloxyjatropha-6(17),11E-diene-9,14-dione|euphodendrophane G
Glu Phe Phe Arg
Glu Phe Arg Phe
Glu Arg Phe Phe
Phe Glu Phe Arg
Phe Glu Arg Phe
Phe Phe Glu Arg
Phe Phe Arg Glu
Phe Phe Val Trp
C34H39N5O5 (597.2951043999999)
Phe Phe Trp Val
C34H39N5O5 (597.2951043999999)
Phe Ile Arg Tyr
Phe Ile Tyr Arg
Phe Leu Arg Tyr
Phe Leu Tyr Arg
Phe Arg Glu Phe
Phe Arg Phe Glu
Phe Arg Ile Tyr
Phe Arg Leu Tyr
Phe Arg Tyr Ile
Phe Arg Tyr Leu
Phe Val Phe Trp
C34H39N5O5 (597.2951043999999)
Phe Val Trp Phe
C34H39N5O5 (597.2951043999999)
Phe Trp Phe Val
C34H39N5O5 (597.2951043999999)
Phe Trp Val Phe
C34H39N5O5 (597.2951043999999)
Phe Tyr Ile Arg
Phe Tyr Leu Arg
Phe Tyr Arg Ile
Phe Tyr Arg Leu
His Lys Lys Trp
His Lys Gln Trp
His Lys Trp Lys
His Lys Trp Gln
His Gln Lys Trp
His Gln Trp Lys
His Trp Lys Lys
His Trp Lys Gln
His Trp Gln Lys
Ile Phe Arg Tyr
Ile Phe Tyr Arg
Ile Arg Phe Tyr
Ile Arg Tyr Phe
Ile Tyr Phe Arg
Ile Tyr Arg Phe
Lys His Lys Trp
Lys His Gln Trp
Lys His Trp Lys
Lys His Trp Gln
Lys Lys His Trp
Lys Lys Trp His
Lys Gln His Trp
Lys Gln Trp His
Lys Trp His Lys
Lys Trp His Gln
Lys Trp Lys His
Lys Trp Gln His
Leu Phe Arg Tyr
Leu Phe Tyr Arg
Leu Arg Phe Tyr
Leu Arg Tyr Phe
Leu Tyr Phe Arg
Leu Tyr Arg Phe
Pro Arg Tyr Tyr
Pro Tyr Arg Tyr
Pro Tyr Tyr Arg
Gln His Lys Trp
Gln His Trp Lys
Gln Lys His Trp
Gln Lys Trp His
Gln Trp His Lys
Gln Trp Lys His
Arg Glu Phe Phe
Arg Phe Glu Phe
Arg Phe Phe Glu
Arg Phe Ile Tyr
Arg Phe Leu Tyr
Arg Phe Tyr Ile
Arg Phe Tyr Leu
Arg Ile Phe Tyr
Arg Ile Tyr Phe
Arg Leu Phe Tyr
Arg Leu Tyr Phe
Arg Pro Tyr Tyr
Arg Tyr Phe Ile
Arg Tyr Phe Leu
Arg Tyr Ile Phe
Arg Tyr Leu Phe
Arg Tyr Pro Tyr
Arg Tyr Tyr Pro
Val Phe Phe Trp
C34H39N5O5 (597.2951043999999)
Val Phe Trp Phe
C34H39N5O5 (597.2951043999999)
Val Trp Phe Phe
C34H39N5O5 (597.2951043999999)
Trp Phe Phe Val
C34H39N5O5 (597.2951043999999)
Trp Phe Val Phe
C34H39N5O5 (597.2951043999999)
Trp His Lys Lys
Trp His Lys Gln
Trp His Gln Lys
Trp Lys His Lys
Trp Lys His Gln
Trp Lys Lys His
Trp Lys Gln His
Trp Gln His Lys
Trp Gln Lys His
Trp Val Phe Phe
C34H39N5O5 (597.2951043999999)
Tyr Phe Ile Arg
Tyr Phe Leu Arg
Tyr Phe Arg Ile
Tyr Phe Arg Leu
Tyr Ile Phe Arg
Tyr Ile Arg Phe
Tyr Leu Phe Arg
Tyr Leu Arg Phe
Tyr Pro Arg Tyr
Tyr Pro Tyr Arg
Tyr Arg Phe Ile
Tyr Arg Phe Leu
Tyr Arg Ile Phe
Tyr Arg Leu Phe
Tyr Arg Pro Tyr
Tyr Arg Tyr Pro
Tyr Tyr Pro Arg
Tyr Tyr Arg Pro
tris(2,2,6,6-tetramethyl-3,5-heptanedionato)titanium (iii)
5H-Dibenzo(a,d)cycloheptene-2,8-dicarboxamide, 5-((2S)-2-((2-((2S)-2-cyano-1-pyrrolidinyl)-2-oxoethyl)amino)propyl)-10,11-dihydro-N2,N2,N8,N8-tetramethyl-5-(2H-tetrazol-5-yl)-
C32H39N9O3 (597.3175703999999)
Mycaminosyltylonolide
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007933 - Leucomycins Mycaminosyltylonolide is a potent antibiotic. Mycaminosyltylonolide shows antibacterial activity. Mycaminosyltylonolide inhibits luciferase synthesis[1][2].
Cytarabine ocfosfate
C27H49N3NaO8P (597.3154804000001)
D000970 - Antineoplastic Agents
revefenacin
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03B - Other drugs for obstructive airway diseases, inhalants > R03BB - Anticholinergics C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Revefenacin (TD-4208; GSK1160724) is a potent mAChR antagonist; has a high affinity on M3 receptor with a Ki of 0.18 nM.
(2E,4E,9R)-9-hydroxy-10-[(2R,4R,6S)-6-[(S)-[[(2S)-2-hydroxy-2-[(2R,5R,6R)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]acetyl]amino]-methoxymethyl]-4-methoxy-3,3-dimethyloxan-2-yl]deca-2,4-dienoic acid
salinisporamycin A
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D012294 - Rifamycins
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide
C31H43N5O7 (597.3162328000001)
1-(2,4-Dimethoxyphenyl)-3-(2,6-dimethylphenyl)-1-[6-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]urea
N-[[(3R,9R,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[(3S,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide
N-[[(3S,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[(3S,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide
N-[[(3R,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[(3R,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide
N-[(3R,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide
N-[[(3S,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(3S,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(3R,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(3S,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[(3S,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide
N-[[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(3S,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(3S,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[(3S,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide
N-[(3R,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide
N-[(3R,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide
N-[[(3S,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[(3S,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide
N-[(3R,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide
N-[(3R,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide
C31H43N5O7 (597.3162328000001)
N-[[(3S,9R,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[[(3R,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
N-[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide
N-[[(3R,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-16-[[oxo-(propan-2-ylamino)methyl]amino]-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methyl-4-pyridinecarboxamide
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-nonoxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoxy]propan-2-yl] propanoate
[2-hexanoyloxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]propan-2-yl] pentanoate
[2-acetyloxy-3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-butanoyloxy-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propan-2-yl] nonanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]propan-2-yl] heptanoate
[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-pentanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate
[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-propanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydodecan-2-yl]propanamide
C27H51NO13 (597.3360236000001)
N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyundecan-2-yl]butanamide
C27H51NO13 (597.3360236000001)
N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytridecan-2-yl]acetamide
C27H51NO13 (597.3360236000001)
N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxynonan-2-yl]hexanamide
C27H51NO13 (597.3360236000001)
N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyoctan-2-yl]heptanamide
C27H51NO13 (597.3360236000001)
N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydecan-2-yl]pentanamide
C27H51NO13 (597.3360236000001)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(4E,7E)-deca-4,7-dienoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-dec-4-enoyl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-decanoyloxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate
1-palmitoyl-2-succinyl-sn-glycero-3-phosphoserine
C26H48NO12P (597.2913977999999)
desferrioxamine E(3-)
A hydroxamic acid anion resulting from the removal of a proton from each of the hydroxamic acid groups of desferrioxamine E.
5-O-mycaminosyltylonolide
A macrolide antibiotic that is tylonolide having a beta-D-mycaminosyl residue attached at position 5.
PC(24:5)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
MePC(23:5)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved